English

• 16 May, 2024
  Spago Nanomedical publishes the annual report for 2023
• 6 May, 2024
  NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)
• 2 May, 2024
  Spago Nanomedical interim report January-March 2024
• 24 Apr, 2024
  Spago Nanomedical reports favorable data in breast cancer model with Tumorad
• 16 Apr, 2024
  Spago Nanomedical strengthens management with Head of CMC & Supply
• 7 Feb, 2024
  Spago Nanomedical year-end report January-December, 2023
• 25 Jan, 2024
  The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered
• 18 Jan, 2024
  Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24
• 10 Jan, 2024
  Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01
• 15 Dec, 2023
  Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis